Trial Profile

A phase 3 pivotal study of RAP 219 in focal onset seizures (FOS)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 28 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RAP 219 (Primary)
Indications Seizures
Focus Registrational; Therapeutic Use
Acronyms FOCUS 2

Most Recent Events

28 Apr 2026 New trial record
10 Mar 2026 According to Rapport Therapeutics media release, Company accelerated the initiation of its Phase 3 program in FOS, which is expected to begin in the second quarter of 2026, updated from its previous guidance of initiation in the third quarter of 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com